Treatment-related predictive and prognostic factors in trimodality approach in stage IIIA/N2 non-small cell lung cancer

2Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

While there are no established pretreatment predictive and prognostic factors in patients with stage IIIA/pN2 non-small cell lung cancer (NSCLC) indicating a benefit to surgery as a part of trimodality approach, little is known about treatment-related predictive and prognostic factors in this setting. A literature search was conducted to identify possible treatment-related predictive and prognostic factors for patients for whom trimodality approach was reported on. Overall survival was the primary endpoint of this study. Of 30 identified studies, there were two phase II studies, 5 "prospective" studies, and 23 retrospective studies. No study was found which specifically looked at treatment-related predictive factors of improved outcomes in trimodality treatment. Of potential treatment-related prognostic factors, the least frequently analyzed factors among 30 available studies were overall pathologic stage after preoperative treatment and UICC downstaging. Evaluation of treatment response before surgery and by pathologic tumor stage after induction therapy were analyzed in slightly more than 40% of studies and found not to influence survival. More frequently studied factors-resection status, degree of tumor regression, and pathologic nodal stage after induction therapy as well as the most frequently studied factor, the treatment (in almost 75% studies)-showed no discernible impact on survival, due to conflicting results. Currently, it is impossible to identify any treatment-related predictive or prognostic factors for selecting surgery in the treatment of patients with stage IIIA/pN2 NSCLC.

Cite

CITATION STYLE

APA

Jeremić, B., Casas, F., Dubinsky, P., Gomez-Caamano, A., Čihorić, N., Videtic, G., & Igrutinovic, I. (2018, February 20). Treatment-related predictive and prognostic factors in trimodality approach in stage IIIA/N2 non-small cell lung cancer. Frontiers in Oncology. Frontiers Media S.A. https://doi.org/10.3389/fonc.2018.00030

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free